Dugo Laura, Collin Marika, Allen David A, Murch Oliver, Foster Simon J, Yaqoob Muhammad M, Thiemermann Christoph
Centre for Experimental Medicine, Nephrology and Critical Care Medicine, The William Harvey Research Institute, St. Bartholomew's and The Royal London School of Medicine and Dentistry, Charterhouse Square, London, UK.
Crit Care Med. 2006 May;34(5):1489-96. doi: 10.1097/01.CCM.0000215457.83953.E3.
Insulin reduces morbidity and mortality among critically ill patients, but the molecular mechanisms of its effect remain unknown. Insulin is a well-known inhibitor of glycogen synthase kinase-3, which may play an important role in systemic inflammation and shock. Here we investigate the role of blood glucose and glycogen synthase kinase-3beta inhibition in the protective effect of insulin on the organ injury/dysfunction associated with excessive systemic inflammation.
Prospective, randomized study.
University-based research laboratory.
Eighty-five anesthetized Wistar rats.
Rats received Escherichia coli lipopolysaccharide (1 mg/kg) and Staphylococcus aureus peptidoglycan (0.3 mg/kg) or vehicle intravenously. Insulin (1.4 units/kg intravenously) was administered in the absence or presence of continuous glucose administration (4.5 mg/kg/hr intravenously) either prophylactically or therapeutically. The potent and selective glycogen synthase kinase-3beta inhibitor TDZD-8 (1 mg/kg intravenously) or vehicle (10% dimethyl sulfoxide) was administered either prophylactically or therapeutically.
Coadministration of lipopolysaccharide and peptidoglycan resulted in increases in the serum levels of creatinine (indicator of renal dysfunction), alanine aminotransferase, and aspartate aminotransferase (indicators of liver injury) at 6 hrs. Insulin or TDZD-8 similarly attenuated the organ injury/dysfunction caused by lipopolysaccharide and peptidoglycan when given either prophylactically or therapeutically. Continuous glucose administration had no effect on blood glucose levels or organ injury/dysfunction at 6 hrs. Treatment with insulin or TDZD-8 reduced the plasma levels of the proinflammatory cytokine interleukin-1beta. In vitro, insulin or TDZD-8 caused similar reductions in the nuclear factor-kappaB p65 activity and similar increases in the phosphorylation of Ser9 of glycogen synthase kinase-3beta.
Therapy with insulin or the potent and selective glycogen synthase kinase-3beta inhibitor TDZD-8 reduced the organ injury/dysfunction caused by lipopolysaccharide and peptidoglycan in the rat. We propose that the inhibitory effect of insulin on the activity of glycogen synthase kinase-3beta contributes to the protective effect of insulin against the organ injury/dysfunction caused by excessive systemic inflammation independently of any effects on blood glucose.
胰岛素可降低重症患者的发病率和死亡率,但其作用的分子机制尚不清楚。胰岛素是糖原合酶激酶-3的知名抑制剂,该酶可能在全身炎症和休克中起重要作用。在此,我们研究血糖和糖原合酶激酶-3β抑制在胰岛素对与过度全身炎症相关的器官损伤/功能障碍的保护作用中的作用。
前瞻性随机研究。
大学研究实验室。
85只麻醉的Wistar大鼠。
大鼠静脉注射大肠杆菌脂多糖(1 mg/kg)和金黄色葡萄球菌肽聚糖(0.3 mg/kg)或赋形剂。胰岛素(1.4单位/kg静脉注射)在有无持续葡萄糖输注(4.5 mg/kg/小时静脉注射)的情况下预防性或治疗性给药。强效选择性糖原合酶激酶-3β抑制剂TDZD-8(1 mg/kg静脉注射)或赋形剂(10%二甲亚砜)预防性或治疗性给药。
脂多糖和肽聚糖联合给药6小时后,血清肌酐水平(肾功能障碍指标)、丙氨酸转氨酶和天冬氨酸转氨酶水平(肝损伤指标)升高。胰岛素或TDZD-8预防性或治疗性给药时,同样可减轻脂多糖和肽聚糖引起的器官损伤/功能障碍。持续葡萄糖输注对6小时时的血糖水平或器官损伤/功能障碍无影响。胰岛素或TDZD-8治疗可降低促炎细胞因子白细胞介素-1β的血浆水平。在体外,胰岛素或TDZD-8可使核因子-κB p65活性类似降低,糖原合酶激酶-3β的Ser9磷酸化类似增加。
胰岛素或强效选择性糖原合酶激酶-3β抑制剂TDZD-8治疗可减轻大鼠脂多糖和肽聚糖引起的器官损伤/功能障碍。我们认为,胰岛素对糖原合酶激酶-3β活性的抑制作用有助于胰岛素对过度全身炎症引起的器官损伤/功能障碍的保护作用,而与对血糖的任何影响无关。